Emerald Mutual Fund Advisers Trust Raises Stake in Mirum Pharmaceuticals, Inc. $MIRM

Emerald Mutual Fund Advisers Trust increased its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 3.3% during the 1st quarter, HoldingsChannel reports. The fund owned 250,399 shares of the company’s stock after buying an additional 8,079 shares during the period. Mirum Pharmaceuticals accounts for approximately 1.1% of Emerald Mutual Fund Advisers Trust’s portfolio, making the stock its 22nd biggest holding. Emerald Mutual Fund Advisers Trust’s holdings in Mirum Pharmaceuticals were worth $23,132,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Faithward Advisors LLC increased its stake in shares of Mirum Pharmaceuticals by 0.5% during the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock valued at $2,537,000 after purchasing an additional 126 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Mirum Pharmaceuticals by 6.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock valued at $253,000 after purchasing an additional 200 shares during the last quarter. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares in the last quarter. Osaic Holdings Inc. boosted its position in shares of Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares in the last quarter. Finally, Cullen Frost Bankers Inc. purchased a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $30,000.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the sale, the senior vice president owned 3,114 shares of the company’s stock, valued at approximately $373,680. This trade represents a 46.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the transaction, the chief financial officer owned 42,181 shares of the company’s stock, valued at $5,156,627.25. This represents a 10.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 65,315 shares of company stock valued at $6,991,928. Corporate insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Trading Down 2.5%

NASDAQ:MIRM opened at $119.04 on Tuesday. The stock has a market cap of $7.26 billion, a price-to-earnings ratio of -8.75 and a beta of 0.48. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The company’s 50 day moving average price is $106.93 and its 200-day moving average price is $98.12. Mirum Pharmaceuticals, Inc. has a 52 week low of $50.25 and a 52 week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The firm had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.Mirum Pharmaceuticals’s revenue was up 43.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MIRM. Stifel Nicolaus set a $136.00 price objective on Mirum Pharmaceuticals in a research report on Thursday, May 7th. Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Morgan Stanley raised their price target on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, June 11th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $143.40.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.